MRD Ad Board Q4 2023

DeciBio conducted 10 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care. Key themes discussed include overviews of which indications have the most MRD/monitoring clinical utility, top selection criteria for ctDNA assays, feedback related to assay vendors, and drivers / moderators relevant to increased use.This report provides a qualitative summary of these interviews. In response to each key interview question, DeciBio provides several condensed takeaways and a curated list of quotes indicative of stakeholder feedback.

‍

This report is organized around the responses to 15 key study questions

‍

• Clinically, what has changed in MRD / monitoring over the past 6 months?
• In biopharma / clinical trials, what has changed in MRD / monitoring over the past 6 months?
• How has reimbursement impacted the adoption of MRD?
• How is testing expected to change over the next 6-12 months?
• What is your level of agreement with each of the following hypotheses over the next two years? (hypotheses discussed include sensitivity and approach, reimbursement, and commercial considerations)
• What vendors are you using and how satisfied are you with them?
• How do vendors compare across key attributes?
• What is the trade-off between sensitivity, approach, and cost?
• What are the strengths / weaknesses across each of the MRD / monitoring vendors you have used?

‍

Companies Discussed

• C2i
• Delfi
• Foundation Medicine
• Grail
• Guardant Health
• Invitae / ArcherDx
• Natera
• NeoGenomics
• Personalis
• Others

‍